. "101441" . "N" . "[C22E8AAC4500]" . . . "2"^^ . . "1"^^ . "Rusina, Robert" . "The primary objective is to assess the clinical activity based on assessment of cognitive and functional domains of repeated immunizations of AD patients in an early stage with AFFITOPE\u00AE AD02. The secondary objective is to assess immunological activity, the overall clinical activity, the impact on health-related quality of life, the treatment effect on the biomarker brain atrophy as well as the safety and tolerability of the Alzheimer AFFITOPE\u00AE AD02 vaccine."@en . "Randomizovan\u00E9, kontrolovan\u00E9, multicentrick\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze 2 s paraleln\u00EDmi skupinami s c\u00EDlem vyhodnotit klinickou a imunologickou aktivitu, bezpe\u010Dnost a sn\u00E1\u0161enlivost r\u016Fzn\u00FDch d\u00E1vek a forem p\u0159\u00EDpravku AFFITOPE AD02 pod\u00E1van\u00E9ho opakovan\u011B pacient\u016Fm v ran\u00E9m st\u00E1diu Alzheimerovy choroby" . "Randomizovan\u00E9, kontrolovan\u00E9, multicentrick\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze 2 s paraleln\u00EDmi skupinami s c\u00EDlem vyhodnotit klinickou a imunologickou aktivitu, bezpe\u010Dnost a sn\u00E1\u0161enlivost r\u016Fzn\u00FDch d\u00E1vek a forem p\u0159\u00EDpravku AFFITOPE AD02 pod\u00E1van\u00E9ho opakovan\u011B pacient\u016Fm v ran\u00E9m st\u00E1diu Alzheimerovy choroby" . . . "RIV/00064190:_____/13:#0000728!RIV14-MZ0-00064190" . . . . "RIV/00064190:_____/13:#0000728" . "Randomizovan\u00E9, kontrolovan\u00E9, multicentrick\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze 2 s paraleln\u00EDmi skupinami s c\u00EDlem vyhodnotit klinickou a imunologickou aktivitu, bezpe\u010Dnost a sn\u00E1\u0161enlivost r\u016Fzn\u00FDch d\u00E1vek a forem p\u0159\u00EDpravku AFFITOPE AD02 pod\u00E1van\u00E9ho opakovan\u011B pacient\u016Fm v ran\u00E9m st\u00E1diu Alzheimerovy choroby"@cs . "A randomised, controlled, parallel group, double-blind, multi-center, phase II study to assess the clinical- and immunological activity as well as the safety and tolerability of different doses/formulations of AFFITOPE AD02 administered repeatedly to patients with early Alzheimer\u2019s disease."@en . . . "AFFIRIS AG" . "Praha" . "Hlavn\u00EDm c\u00EDlem je zhodnotit klinickou aktivitu na z\u00E1klad\u011B posouzen\u00ED kognitivn\u00EDch a funk\u010Dn\u00EDch dom\u00E9n opakovan\u00E9ho o\u010Dkov\u00E1n\u00ED pacient\u016F s AD v ran\u00E9 f\u00E1zi AFFITOPE \u00AE AD02. Druhotn\u00FDm c\u00EDlem je zhodnotit imunologickou aktivitu, celkovou klinickou aktivitu, vliv na kvalitu souvisej\u00EDc\u00ED se zdrav\u00EDm \u017Eivota, l\u00E9\u010Debn\u00FD \u00FA\u010Dinek na biomarker\u016F mozkov\u00E9 atrofie, stejn\u011B jako bezpe\u010Dnost a sn\u00E1\u0161enlivost vakc\u00EDny Alzheimerovy choroby AFFITOPE \u00AE AD02."@cs . "Hlavn\u00EDm c\u00EDlem je zhodnotit klinickou aktivitu na z\u00E1klad\u011B posouzen\u00ED kognitivn\u00EDch a funk\u010Dn\u00EDch dom\u00E9n opakovan\u00E9ho o\u010Dkov\u00E1n\u00ED pacient\u016F s AD v ran\u00E9 f\u00E1zi AFFITOPE \u00AE AD02. Druhotn\u00FDm c\u00EDlem je zhodnotit imunologickou aktivitu, celkovou klinickou aktivitu, vliv na kvalitu souvisej\u00EDc\u00ED se zdrav\u00EDm \u017Eivota, l\u00E9\u010Debn\u00FD \u00FA\u010Dinek na biomarker\u016F mozkov\u00E9 atrofie, stejn\u011B jako bezpe\u010Dnost a sn\u00E1\u0161enlivost vakc\u00EDny Alzheimerovy choroby AFFITOPE \u00AE AD02." . "1"^^ . "Alzheimer disease"@en . "Randomizovan\u00E9, kontrolovan\u00E9, multicentrick\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze 2 s paraleln\u00EDmi skupinami s c\u00EDlem vyhodnotit klinickou a imunologickou aktivitu, bezpe\u010Dnost a sn\u00E1\u0161enlivost r\u016Fzn\u00FDch d\u00E1vek a forem p\u0159\u00EDpravku AFFITOPE AD02 pod\u00E1van\u00E9ho opakovan\u011B pacient\u016Fm v ran\u00E9m st\u00E1diu Alzheimerovy choroby"@cs . . . "A randomised, controlled, parallel group, double-blind, multi-center, phase II study to assess the clinical- and immunological activity as well as the safety and tolerability of different doses/formulations of AFFITOPE AD02 administered repeatedly to patients with early Alzheimer\u2019s disease."@en .